← Leaderboards
Kathleen R Chirco
University Of California, San Francisco
$1,017,200
Attributed
$1,017,200
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $249K · FY2020–25$250K$187.5K$125K$62.5K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,017,200 · 3
By mechanism
R00$746,998 · 1
F32$180,678 · 1
K99$89,524 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Michael T McManus$36,428,993
- Claire Clelland$2,800,410
- Nadav Ahituv$31,471,722
- Deepak Ashok Lamba$4,257,564
- Martin Kampmann$17,201,095
Others in their field
Other Emerging Leaders on “Mutation”
- Leonard Freedman · Leidos Biomedical Research, Inc.$85,874,322
- John Damon Chodera · Sloan-Kettering Inst Can Research$48,421,310
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$38,744,543
- Lynn Briscoe · Leidos Biomedical Research, Inc.$38,032,945
- Maria C Carrillo · Indiana University Indianapolis$19,445,642
- James Dale Berry · Brigham And Women'S Hospital$19,118,191
Research focus
MutationRetinal DegenerationInduced Pluripotent Stem CellMediatingPhenotypeRetinaDisease PhenotypeGenesInvestigationLeadOrganoidsBiological ModelsEffective TherapyPhotoreceptorsCrispr/Cas TechnologyCell PhysiologyFunctional DisorderFutureDisease ModelInheritedIn VitroIn VivoAffectRetinal Diseases
Grant awards (8)
Establishing a novel gene editing strategy for BBS7 using human retinal organoids$249,000
R00 · FY2025 · EY · contact PI
Establishing a novel gene editing strategy for BBS7 using human retinal organoids$248,998
R00 · FY2024 · EY · contact PI
Establishing a novel gene editing strategy for BBS7 using human retinal organoids$249,000
R00 · FY2023 · EY · contact PI
Establishing a novel gene editing strategy for BBS7 using human retinal organoids$89,524
K99 · FY2022 · EY · contact PI
Disease modeling and CRISPR/Cas9-mediated rescue of dominant Leber congenital amaurosis retinal phenotypes$42,774
F32 · FY2022 · EY · contact PI
Disease modeling and CRISPR/Cas9-mediated rescue of dominant Leber congenital amaurosis retinal phenotypes$70,458
F32 · FY2021 · EY · contact PI
Disease modeling and CRISPR/Cas9-mediated rescue of dominant Leber congenital amaurosis retinal phenotypes$34,103
F32 · FY2020 · EY · contact PI
Disease modeling and CRISPR/Cas9-mediated rescue of dominant Leber congenital amaurosis retinal phenotypes$33,343
F32 · FY2020 · EY · contact PI